Mar 25, 2024
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
Mar 22, 2024
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Mar 20, 2024
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Mar 15, 2024
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
Mar 07, 2024
AIM ImmunoTech Announces Launch of CEO Corner Platform
Feb 29, 2024
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
Feb 14, 2024
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
Feb 08, 2024
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Jan 24, 2024
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
Jan 22, 2024
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca's Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
 1     2    3   4   5   6   7 
 <<   <   >   >>